Skip to content

ASCA-PD study

The antibiotic effect of silver CAPD catheter on peritoneal dialysis-related infections : a multicenter randomized open-label trial - ASCA-PD study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs052250003
Enrollment
250
Registered
2025-04-07
Start date
2025-05-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal failure End-stage kidney disease, peritoneal dialysis, peritoneal dialysis catheter-related infections

Interventions

Randomization of catheters inserted into the peritoneal cavity at the time of induction of peritoneal dialysis, silver CAPD catheters or conventional catheters
D004867

Sponsors

Tsuruya Kazuhiko
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: New planned peritoneal dialysis initiation patients Age restriction: 18 years and older

Exclusion criteria

Exclusion criteria: 1)Patients requiring reintroduction after kidney transplantation or hemodialysis 2)Emergency peritoneal dialysis initiation patients 3)Cases involving the creation of an exit site in special locations with extended catheters (excluding upper abdominal exit sites) 4)Patients with a history of metal allergies, including sensitivity to silver. 5)Patients with a prognosis of less than one year at the time of initiation (e.g., terminal cancer patients) 6)Patients with a history of Severe liver cirrhosis (Child-Pugh grade C) 7)Complications with skin conditions such as common infections or atopic dermatitis 8)Patients with gastrostomy or colostomy 9)Use of immunosuppressants (including oral and/or intravenous corticosteroids administration)

Design outcomes

Primary

MeasureTime frame
All exit-site and tunnel infections (composite endpoint) occurring within 12 months after exit-site formation (peritoneal dialysis initiation)

Secondary

MeasureTime frame
1) All exit-site and tunnel infections occurring within 12 months after exit-site creation (peritoneal dialysis initiation), with catheter removal not due to infection considered and death. 2) The first occurrence of exit-site and tunnel infections within 12 months after exit-site creation (peritoneal dialysis initiation). 3) The first occurrence of exit-site and tunnel infections within 12 months after exit-site creation (peritoneal dialysis initiation), with catheter removal not due to infection and death considered as competing risk factors. 4) Exit-site and tunnel infections occurring within 30 days after exit-site creation (peritoneal dialysis initiation). 5) All cases of peritonitis occurring after catheter insertion. 6) Catheter removal after catheter insertion (regardless of the reason for removal). 7) Catheter removal due to infection, exit-site or tunnel infections requiring surgical intervention, subcutaneous cuff extrusion, and death within 30 days due to peritonitis after catheter insertion. 8) Catheter patency. 9) Allergic reactions such as contact dermatitis, eosinophilia, and eosinophilic peritonitis after catheter insertion. 10) Refractory or recurrent exit-site infections, tunnel infections, and peritonitis. 11) Presence of colony formation at the exit site and culture results at the end of observation (12 months after exit-site creation or at the time of catheter removal within 12 months). 12) Technique failure (transition to hemodialysis for more than 30 days, or death) *Note: Kidney transplantation is censored. 13) Transition from peritoneal dialysis to hybrid therapy (combination of hemodialysis and peritoneal dialysis).

Contacts

Public ContactMasahiro Eriguchi

Nara Medical University Hospital

meriguci@naramed-u.ac.jp+81-744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026